Lentivirus Production

Lentivirus Production services provide a comprehensive set of high-titer and high-throughput lentiviral solutions, spanning construct synthesis through viral production plus storage of transduction-ready virus. Lentiviral vectors are broadly used in laboratories across academia and industry for research and clinical gene therapy applications. Gene therapy vectors derived from lentivirus offer an array of unique advantages over traditional retroviral gene delivery systems. Leading these is their ability to provide long-term and stable gene expression and robust infection of both dividing and non-dividing cells, such as neurons.

With GENEWIZ Multiomics and Synthesis Solutions from Azenta Life Sciences, you can enjoy the convenience of an end-to-end solution to advance your research.

Applications of Lentivirus Vectors

Stable Protein Expression: Transduce cells with transgene-containing lentiviral vectors for cell line generation

Gene and Cell Therapy: Treat diseases by delivery of genetic material through cell or gene therapies such as CAR T-cell and gene replacement

Genome Engineering: Use viral vectors to deliver CRISPR/Cas9 or shRNA-mediated gene editing platforms

Lentivirus Production

Starting at €280 / £245

What Are the Advantages of Lentivirus?

Lentiviral vectors are research tools used to introduce gene products into in vitro systems, animal models, or human patients via cell therapy. Lentiviruses have a broad range of applications and are commonly used in clinical cell therapy as well as in CAR-T cell engineering.

Lentiviral vectors can carry relatively large transgenes
Low immunogenicity
Can be used for gene editing (e.g. deliver CRISPR elements to the cell)
Ability to transduce both dividing and non-dividing cells
Integration into the host genome and stable expression of the transgene

For more lentivirus frequently asked questions (FAQs) please visit our lentivirus FAQ page.

Lentiviral Packaging Workflow

GENEWIZ Lentiviral Packaging Advantages

Convenience - One-stop shop from gene synthesis or plasmid prep to lentivirus packaging
Flexible Synthesis Options - A variety of viral prep scales with high-titer transduction-ready virus available (>65% of all packaging achieved ~3-fold higher than the quoted amount)
Fit-for-Screening Deliverables - High-throughput lentiviral workflows accelerate your downstream screening applications (CRISPR/Cas9, shRNA, etc.)

Rigorous Quality Control - Functional titering option available
Dedicated Ph.D.-Level Support – Support at every step with real-time project updates through our online system
Scalable Project Design – Take your previously synthesized lentiviral plasmids directly to prep and packaging

Lentivirus Production Offerings

Lentivirus Production

Virus Titer	Volume Available	Estimated Completion Time*	Quality Control
>10⁸ IFU/mL	250µL - 500µL, 1mL - 1.5mL	In as few as 2 weeks (~90% of the projects are delivered ahead of the projected TAT)	Default titration by p24 ELISA, functional titering by qPCR available upon request
>10⁹ IFU/mL	250µL - 500µL, 1mL - 1.5mL

*Starting with ready-to-transfect transfer plasmid DNA at the recommended amount

High-Throughput Lentivirus Production

Workflow	Pooled Format	Arrayed Format
Plasmid Generation	Oligo pool synthesis and high-throughput cloning into lentiviral plasmid of your choice, constructing a plasmid library	Standard gene synthesis/cloning to generate individual clonal plasmid constructs which go through the same stringent QC process
Plasmid Preparation	Transfection-grade plasmid DNA preparation of either clonal or library plasmids before lentivirus production
Lentivirus Packaging	LV packaging of plasmid library, delivering LV particles at either 10⁸ IFU/ml or 10⁹ IFU/ml titers with various volume options (250ul, 500ul, 1ml, 1.5ml, etc.)	High-throughput packaging of a large quantity of arrayed plasmids, delivering LV particles in 96-well plates with 50-100ul volume per well

**Third Generation* Lentiviral Vectors**

Component	Options
Promoter	CMV, EF1α, U6, etc.
Selection Marker	Puromycin, Hygromycin, Neomycin, etc.
Fluorescent Marker	GFP, etc.
Custom Cargo Design	De novo synthesis of the entire LTR to LTR cassette to meet all requirements

*Third generation is our default lentivirus packaging workflow and, if required, second generation can be accommodated upon review

SECOND VS THIRD GENERATION LENTIVIRUS SYSTEMS

Component	Second Generation	Third Generation
Transfer Plasmid	Can be packaged ONLY by a second-generation packaging system	Can be packaged by both second and third generation packaging systems
Packaging Plasmid	Plasmids includes Gag, Pol, Rev, Tat for entry and integration of the viral genome	Plasmids include only packaging genes Gag and Pol
Envelope Plasmid	Contains gene encoding for envelope proteins	Contains gene encoding for envelope proteins
Safety	Safe. Replication incompetent: uses 3 separate plasmids encoding various HIV genes	Safer. Transfer plasmids are all replication incompetent rendering the virus “self-inactivating” (SIN) after integration.
Titer	Standard to high viral yield	Higher viral yield

Technical Resources

Tech Note | Enhancing Protein Expression by Leveraging Codon Optimization

Codon preference is among the most critical parameters affecting the expression level of foreign genes. This technical note will discuss two practical case studies, comparing wild-type gene performance to Azenta codon-optimized sequences.

Infographic | Lentiviral Vector Packaging for Enhanced Downstream Research

The vectors derived from lentivirus offer an array of unique advantages over traditional retroviral gene delivery systems, but the process can be tedious and complex. Learn more about the critical steps and factors to consider when producing lentivirus for enhancing your downstream research.

Blog | Lentivirus Production for Gene Delivery

Lentiviruses are one of the most utilized viral delivery systems for cell and gene therapy because they have broad host-cell tropism and offer stable integration into the host cell. Here, we discuss how lentiviruses have been engineered to deliver transgenes safely and how researchers today generate lentiviral preparations.

Poster | Optimizing mRNA Vaccines and Virus-Mediated CAR T-Cell Therapy for Immuno-Oncology

Lentiviral vectors have proven effective at delivery of genetic material or gene editing technology for ex vivo processing, but the benefits and promise of Adeno-associated virus (AAV) and mRNA tools for in vivo immunotherapy have garnered recent interest. In this poster, we present streamlined approaches for lentiviral, AAV, and mRNA production that improves data quality through innovative synthesis and sequencing methodologies as compared to current standards.